GeneTex, Inc.
6.6.2023 15:05:40 CEST | ACCESS Newswire | Press release
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production23.10.2026 18:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / October 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in Uncrewed Aircraft Systems (UAS), today is announcing our partnership with Spirit Defense, a Boeing Company, to support airframe production of the new FQ-42 Vengeance Collaborative Combat Aircraft (CCA). In June, GA-ASI won a contract from the U.S. Air Force (USAF) to produce FQ-42. Spirit Defense's role as a fuselage design-build partner brings together the company's engineering and advanced manufacturing capabilities to support the program from design through production. GA-ASI has been the sole manufacturer of its line of UAS - which includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian - since the company's inception in 1992. For the FQ-42 program, partnering with Spirit Defense is a strength multiplier for the company and the nation, offering manufacturing capacity and industrial depth to scale CCA production faster, w
Study Finds Lower Rates of Overweight Among Vegan-Fed Cats23.10.2026 16:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats fed either conventional meat-based (90%) or vegan (10%) diets for at least one year. After accounting for factors including age, sex, neuter status, activity and feeding practices, vegan-fed cats had 34% lower odds of being assessed as overweight. However, the difference was not statistically significant, in part reflecting the relatively small number of vegan-fed cats. For several body weight-related problems, no vegan-fed cats were affected. Nevertheless, researchers say the findings show an interesting trend that warrants further investigation. Overweight and obesity are common in domestic cats, with veterinary studies estimating that around 30-60% of cats are overw
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award23.10.2026 16:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications. The judging panel cited MCM's innovation that achieves affordable, premium-level comfort for mid-class vehicle programs. About Leggett Dynamics' Mid-Class Massage System Leggett Dynamics' MCM is a comfort innovation that expands premium massage technology beyond the luxury vehicle segment. Already in serial production with a leading global OEM and generating strong interest from multiple global automakers, the innovation delivers a premium massage experience while reducing system cost and complexity through the intelligent use of pre
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom